Wednesday, June 10, 2026

Patent intelligence · AU

AU 2002328956

17alfa, 21-dihydroxypregnene esters as antiandrogenic agents

granted A61K 31/ 573 A IA61K/31573A61K/3170A61K/4706
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 1
Applicant portfolio 12
Patent details — AU 2002328956
Jurisdiction
AU
Status
granted
Grant date
Aug 16, 2007
Expiration
Aug 11, 2027
CPC classes
A61K 31/ 573 A I, A61K/31573, A61K/3170, A61K/4706
View on Google Patents ↗

Quick answer

AU 2002328956 (17alfa, 21-dihydroxypregnene esters as antiandrogenic agents) is held by CASSIOPEA S P A [IT]. Status: granted. Granted Aug 16, 2007. Expires Aug 11, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 31/ 573 A I, A61K/31573, A61K/3170, A61K/4706, A61K/4710, A61K/4712

More from CASSIOPEA S P A [IT]

Related pharmaceutical patents in our USPTO index.

  1. WO 2026087531

    FORMULATIONS DE CLASCOTÉRONE ET LEURS MÉTHODES D'UTILISATION

    CASSIOPEA S P A [IT] · Expires Apr 25, 2046

    granted
  2. WO 2026057588

    POLYTHÉRAPIE À BASE DE CLASCOTÉRONE ET DE MINOXIDIL POUR LE TRAITEMENT DE LA PERTE DES CHEVEUX

    CASSIOPEA S P A [IT] · Expires Mar 14, 2046

    granted
  3. WO 2025172818

    POLYTHÉRAPIE À BASE DE PYRILUTAMIDE

    CASSIOPEA S P A [IT] · Expires Aug 16, 2045

    granted
  4. WO 2025125508

    COMBINAISONS DE CORTEXOLONE-17ΑLPHA-PROPIONATE POUR LE TRAITEMENT DE L'ACNÉ

    CASSIOPEA S P A [IT] · Expires Jun 14, 2045

    granted
  5. AR 132316

    TRATAMIENTO COMBINADO CON CLASCOTERONA Y MINOXIDIL

    CASSIOPEA S P A [IT] · Expires Jun 6, 2045

    granted
  6. WO 2025068281

    CORTÉXOLONE-17α-PROPIONATE POUR LE TRAITEMENT D'ÉRUPTIONS ACNÉIFORMES

    CASSIOPEA S P A [IT] · Expires Mar 29, 2045

    granted
  7. EP 4529925

    CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN

    CASSIOPEA S P A [IT] · Expires Mar 28, 2045

    granted
  8. US 2018169113

    HIGH CONCENTRATION FORMULATION

    CASSIOPEA S P A [IT] · Expires Jun 16, 2038

    granted

Frequently asked questions

What is US patent 2002328956?

AU 2002328956 (17alfa, 21-dihydroxypregnene esters as antiandrogenic agents) is held by CASSIOPEA S P A [IT]. Status: granted. Granted Aug 16, 2007. Expires Aug 11, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.

Who owns AU 2002328956?

CASSIOPEA S P A [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.

When does AU 2002328956 expire?

Our index shows an expiration date of Aug 11, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.